AlphAIAlphAI — Financial news for AI agents
investing.com$EVAX

Evaxion presents phase 2 cancer vaccine biomarker data at SITC

Evaxion A/S (NASDAQ:EVAX) presented phase 2 trial data for its cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer Annual Meeting. The data showed significant T-cell responses and a strong association between its AI-Immunology platform's predictions and actual immune responses. The trial reported an Objective Response Rate of 75% in advanced melanoma patients.

Original reporting
investing.com
Published Nov 6, 2026, 4:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 4:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$EVAX
Bullish
high confidence
Mentioned
$EVAX
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$EVAXBullishMed
01

Why it matters

The Phase 2 results provide the first robust efficacy readout, which could accelerate partnership talks and future financing.

02

Market read

New trial data is material for EVAX and may influence peer biotech valuations and AI‑driven drug development sentiment.

03

What to watch

Regulatory pathway timelines and potential competition from larger immunotherapy players could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

Evaxion A/S (NASDAQ:EVAX) is a Copenhagen‑based biotech developing personalized peptide cancer vaccines using its AI‑Immunology platform.

Company-level read

Ticker impact

$EVAXBullishHigh confidence
Context

Evaxion presented new Phase 2 biomarker data showing 75% objective response rate and strong T‑cell responses in advanced melanoma patients.

Expected impact

likely upward pressure as investors price in strong efficacy signals

Evidence & confidence

The trial showed high response rates and a statistically significant AI‑immunology prediction correlation, which is material for a biotech at this stage.

Market effects

Sector

Strengthens the personalized cancer‑vaccine niche and may boost peer biotech valuations.

Regional

European biotech investors may see increased interest given the Copenhagen‑based company's progress.

Global

Adds credibility to AI‑driven immunotherapy approaches worldwide.

Counterpoint

What could challenge this read

Data may be over‑optimistic; long‑term efficacy and safety still unproven, and market may have priced in early hype.

Key entities

  • company
    Evaxion A/S

    Biotech developing personalized cancer vaccines.

  • partner
    Merck

    Provider of anti‑PD‑1 therapy pembrolizumab used in combination.

Read at source← All news

StoryEvaxion to present phase‑2 biomarker data for personalized cancer vaccine EVX‑01 at SITC 2026

Also covered by

1 outlet

Related articles

$EVAXMedAI 8/10

Evaxion: New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) presented phase 2 trial data for its personalized cancer vaccine EVX-01, showing strong immune responses in advanced melanoma patients. The data, shared at the SITC 2026 Annual Meeting, includes 89% vaccine target precision and sustained T-cell responses. Evaxion's AI-Immunology platform demonstrated strong predictive performance, with significant association between predictions and actual T-cell responses.

finanznachrichten.de
$EVAXMed

Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting

Evaxion A/S (NASDAQ: EVAX) will present new data on EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML), at the ASH 2026 Meeting. The data validate EVX-04's potential, showing broad patient coverage and immune response induction in preclinical models. EVX-04 targets non-conventional endogenous retrovirus (ERV) tumor antigens, selected using Evaxion's AI-Immunology platform.

finanznachrichten.de
$EVAXMedAI 8/10

Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion (NASDAQ: EVAX) will present new biomarker data from its phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting. The trial, involving advanced melanoma patients, showed a 75% objective response rate. EVX-01 is designed with Evaxion's AI-Immunology platform and is being evaluated as a treatment for advanced melanoma.

finanznachrichten.de
$EVAXHighAI 8/10

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion A/S (NASDAQ: EVAX) reported 3-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. The trial showed 89% of vaccine neoantigens generated specific T-cell responses, with sustained immune and clinical responses. The data will be presented at the ESMO 2026 Congress. Evaxion maintains a cash runway into 2027.

finanznachrichten.de